IQWIG -- The pharmaceutical company Pfizer is concealing data on the effect of a drug (Edronax® containing the agent reboxetine) for the treatment of depression. Despite repeated requests by the Institute for Quality and Efficiency in Health Care (IQWiG), Pfizer has refused to provide a complete list of all published and unpublished trials on reboxetine. The Institute discovered through its own literature search that the drug approved in Germany has been tested in at least 16 trials. However, in 9 of these 16 trials, key information is missing that would enable an evaluation of reboxetine's performance.
